Steatohepatitis/Metabolic Liver Disease News

Elysium Health completed enrollment for a clinical trial designed to evaluate the efficacy of Basis, a combination of the company’s proprietary nicotinamide riboside and pterostilbene, on liver fat accumulation in adults with nonalcoholic fatty liver disease, according to a press release.

Dicerna Pharmaceuticals and Novo Nordisk announced an agreement to develop RNA interference therapies for liver-related cardiometabolic diseases, according to a press release.

BOSTON — In this exclusive video from The Liver Meeting 2019, Rosemary Wickowski, co-founder and chief operating officer of the Fatty Liver Foundation, addresses the liver disease community regarding the optimistic future for patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

BOSTON — In this exclusive video from The Liver Meeting 2019, Wayne Eskridge, founder and CEO of the Fatty Liver Foundation, discusses the foundation’s goals for patient advocacy and an upcoming study designed to assess asymptomatic individuals who self-selected for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis screening.

BOSTON — Treatment with MSDC-0602K safely produced positive effects on glycemic control along with consistent improvement in liver enzymes and noninvasive hepatic markers in patients with nonalcoholic steatohepatitis and type 2 diabetes, according to data presented at The Liver Meeting 2019.

BOSTON — Patients with non-alcoholic steatohepatitis treated with licogliflozin experienced dose-dependent improvement in alanine aminotransferase levels and other measures, according to study results presented at the Liver Meeting 2019.

LAS VEGAS — Liver fat volume can be reduced by bariatric surgery regardless of procedure type, although some liver enzymes may be affected differently by sleeve gastrectomy or Roux-en-Y gastric bypass, according to findings presented at ObesityWeek.

BOSTON — In this exclusive video from The Liver Meeting 2019, Tarek Hassanein, MD, FAASLD, professor of medicine at UC San Diego Health and medical director of Southern California GI and Liver Centers, discusses results of a phase 2a study, which demonstrated that DUR-928 was well-tolerated and effective in patients with acute alcoholic hepatitis.

BOSTON — While selonsertib did not demonstrate efficacy as a monotherapy in patients with nonalcoholic steatohepatitis-related advanced fibrosis, data from the trial provided key insights for future trial design and potential for selonsertib in combination therapy, according to data presented at The Liver Meeting 2019.

BOSTON — A machine learning approach demonstrated a relatively high sensitivity rate for predicting the probability of non-alcoholic steatohepatitis in at-risk patients, according to data presented at The Liver Meeting 2019.